Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present ProText Mobility, Inc. (OTC: TXTM).

Full DD Report for TXTM

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.00040.00040.000450.000319,938,899
2018-12-130.00040.00040.00050.000352,111,439
2018-12-120.00030.00040.00050.000310,041,677
2018-12-110.00040.00040.00050.0003539,343,874
2018-12-100.00040.00050.00050.00042,792,206

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-142,394,96719,938,89912.0115Cover
2018-12-13401,3082,111,43919.0064Cover
2018-12-125,211,04210,041,67751.8941Short
2018-12-1114,713,87439,343,87437.3981Short
2018-12-10190,0002,792,2066.8047Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TXTM.


About ProText Mobility, Inc. (OTC: TXTM)

Logo for ProText Mobility, Inc. (OTC: TXTM)

Protext Pharma, Inc. F.K.A. Protext Mobility , operates two wholly owned subsidiaries Plandai Biotechnology South Africa PTY LTD. and Cannabis Biosciences, Inc. The Company is engaged in the research and clinical testing of bioceutical products, all natural ingredients formulated for pharmaceutical applications and processed under pharma grade conditions. Plandai Biotechnology SA, has the exclusive worldwide license to develop pharmaceutical applications and products using the Phytofare catechin complex, which was developed by Plandai Biotechnology, Inc. Phytofare is a highly bioavailable extract produced from live green tea leaves. Our initial product, Phytofare Catechin Complex, has been clinically shown to have times greater bioavailability over generic catechin extracts. Cannabis Biosciences is actively pursuing government licenses and permits that will allow it to use its proprietary processing and extraction technology to commence investigations and produce a full profile cannabis extract, one that contains both CBD and the precursor acid form of THC THC A and THC B found in live cannabis plant. The Company s investigations will be designed to show that the Cannabis Biosciences extraction process, which will use live leaf and low temperatures to extract the phyto chemicals, should leave the acid forms of THC intact, resulting in a non psychoactive extract with full medicinal potential and having the heightened bioavailability of other Phytofare extracts.

 

Contact Information

 

 

Current Management

  • Roger Duffield / CEO
  • David Lewis / Executive Director

Current Share Structure

  • Market Cap: $3,253,053 - 03/16/2018
  • Authorized: 10,000,000,000 - 01/22/2018
  • Issue and Outstanding: 4,066,316,008 - 01/22/2018
  • Float: 1,716,220,028 - 12/14/2016

 


Recent Filings from (OTC: TXTM)

Supplemental Information - Update for Corporate Website
Filing Type: Supplemental Information - Update for Corporate WebsiteFiling Source: OTC Markets
Filing Date: December, 11 2017
Quarterly Report - Protext Q3, 2017
Filing Type: Quarterly Report - Protext Q3, 2017Filing Source: OTC Markets
Filing Date: November, 20 2017
Notification of Late Filing - Notification of Late Filing
Filing Type: Notification of Late Filing - Notification of Late FilingFiling Source: OTC Markets
Filing Date: November, 14 2017

 

 


Daily Technical Chart for (OTC: TXTM)

Daily Technical Chart for (OTC: TXTM)


Stay tuned for daily updates and more on (OTC: TXTM)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: TXTM)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TXTM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of TXTM and does not buy, sell, or trade any shares of TXTM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/